JP2021522865A5 - - Google Patents

Info

Publication number
JP2021522865A5
JP2021522865A5 JP2021513376A JP2021513376A JP2021522865A5 JP 2021522865 A5 JP2021522865 A5 JP 2021522865A5 JP 2021513376 A JP2021513376 A JP 2021513376A JP 2021513376 A JP2021513376 A JP 2021513376A JP 2021522865 A5 JP2021522865 A5 JP 2021522865A5
Authority
JP
Japan
Prior art keywords
nutrient
cell
donor template
cells
vector
Prior art date
Application number
JP2021513376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522865A (ja
JPWO2019217803A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/031699 external-priority patent/WO2019217803A1/en
Publication of JP2021522865A publication Critical patent/JP2021522865A/ja
Publication of JP2021522865A5 publication Critical patent/JP2021522865A5/ja
Publication of JPWO2019217803A5 publication Critical patent/JPWO2019217803A5/ja
Withdrawn legal-status Critical Current

Links

JP2021513376A 2018-05-10 2019-05-10 栄養要求性調節可能な細胞を使用する遺伝子療法の方法および組成物 Withdrawn JP2021522865A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669848P 2018-05-10 2018-05-10
US62/669,848 2018-05-10
PCT/US2019/031699 WO2019217803A1 (en) 2018-05-10 2019-05-10 Gene therapy methods and compositions using auxotrophic regulatable cells

Publications (3)

Publication Number Publication Date
JP2021522865A JP2021522865A (ja) 2021-09-02
JP2021522865A5 true JP2021522865A5 (https=) 2022-05-17
JPWO2019217803A5 JPWO2019217803A5 (https=) 2022-05-17

Family

ID=66794093

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513376A Withdrawn JP2021522865A (ja) 2018-05-10 2019-05-10 栄養要求性調節可能な細胞を使用する遺伝子療法の方法および組成物

Country Status (11)

Country Link
US (1) US20210052741A1 (https=)
EP (1) EP3790974A1 (https=)
JP (1) JP2021522865A (https=)
KR (1) KR20210030902A (https=)
CN (1) CN112513271A (https=)
AU (1) AU2019265916A1 (https=)
BR (1) BR112020022612A2 (https=)
CA (1) CA3098874A1 (https=)
MX (1) MX2020011757A (https=)
SG (1) SG11202010837XA (https=)
WO (1) WO2019217803A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230265440A1 (en) * 2020-06-26 2023-08-24 The Board Of Trustees Of The Leland Stanford Junior University Targeting the human ccr5 locus as a safe harbor for the expression of therapeutic proteins
WO2025080701A1 (en) * 2023-10-11 2025-04-17 William Marsh Rice University Genetically activated mesenchymal stem cells and stromal cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232430A1 (en) 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
CA2608913A1 (en) * 2005-05-18 2006-11-23 Biofactura, Inc. Compositions and methods for metabolic selection of transfected cells
US20090176260A1 (en) 2007-12-04 2009-07-09 Joseph Ching-Ming Wu Double-fusion human embryonic stem cells, methods of making double-fusion human embryonic stem cells, triple-fusion human embryonic stem cells, methods of making triple-fusion human embryonic stem cells, and methods of monitoring double-fusion human embryonic stem cells and triple-fusion human embryonic stem cells
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP3363902B1 (en) 2012-12-06 2019-11-27 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
CA2894684A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
US20160122774A1 (en) 2013-05-29 2016-05-05 Cellectis A method for producing precise dna cleavage using cas9 nickase activity
US11319555B2 (en) * 2014-11-20 2022-05-03 Duke University Compositions, systems and methods for cell therapy
GB201618414D0 (en) * 2016-11-01 2016-12-14 Patterson James Regulated cell lines and methods of use thereof

Similar Documents

Publication Publication Date Title
JP7047002B2 (ja) 化学修飾ｍＲＮＡ
Vile et al. Cancer gene therapy: hard lessons and new courses
EP2646556B1 (en) Novel hybrid promoter and recombinant vector comprising the same
TWI863887B (zh) 使用具有工程化穩定表現內源性foxp3基因之cd4 t細胞治療自體免疫疾病的方法
JP2022000470A (ja) 核酸製品及びその投与方法
JP7173548B2 (ja) 非組み込みウイルス送達系およびその関連方法
EP1019499B1 (en) Methods and compositions for inducing tumor-specific cytotoxicity
TW202043477A (zh) 編碼蛋白質的核糖核酸
JP2022532535A (ja) 栄養要求性選択方法
CN116710079A (zh) 包含经修饰的核苷酸的脂质纳米颗粒
JP2021522865A5 (https=)
CN109929865B (zh) 基于gal4-uas系统的crispr辅助反式增强子激活基因表达的方法及其应用
CN119585419A (zh) 工程化t细胞
KR102832420B1 (ko) 인공 합성 mRNA 및 그 이용
CN116064676A (zh) CRISPRa介导的间充质干细胞制备胰岛素分泌细胞的方法
CN118652889B (zh) 一种环状核酶系统及其应用
JPWO2019217803A5 (https=)
KR20210030902A (ko) 영양요구 조절가능 세포를 사용한 유전자 요법 방법 및 조성물
CN113215105B (zh) Elmo2过表达间充质干细胞的构建及其在骨折治疗中的应用
RU2020140605A (ru) Способы и композиции для генной терапии с использованием ауксотрофных регулируемых клеток
US20240060083A1 (en) Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of SHH, CTNNB1, NOG, and WNT7A genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-SHH, or Escherichia coli strain SCS110-AF/VTvaf17-CTNNB1, or Escherichia coli strain SCS110-AF/VTvaf17-NOG, or Escherichia coli strain SCS110-AF/VTvaf17-WNT7A carrying the gene therapy DNA vector, method
KR20220017927A (ko) 영양요구 조절가능 세포를 사용한 방법 및 조성물
EP4136237A1 (en) Forskolin-inducible promoters and hypoxia-inducible promoters
CN116064402A (zh) CRISPRa和化学诱导联合制备胰岛素分泌细胞的方法
Babu et al. Cancer gene therapies progress in pre and postgenomics era